Retrogenix advances medical research and speeds up drug discovery for clients by providing a unique service which identifies specific cell surface protein interactions in human cells. Retrogenix now has research agreements with 19 of the top 20 global pharmaceutical companies, numerous drug discovery and biotech companies and many leading academic and non-for-profit institutions around the world.
Our results have been published in high-impact journals including Nature, Molecular Cancer, Cancer Cell, mBio and Oncotarget and members of our team are regularly invited to present at international conferences. In 2015 and 2017, Retrogenix won Queen’s Awards for Enterprise and International Trade, respectively – the UK’s most prestigious business accolade – in recognition of its innovative work in developing and commercialising the cell microarray technology.
As well as the unique cell microarray technology, Retrogenix also holds one of the world’s largest collections of plasma membrane protein clones which are individually expressed in human cells. The collection now exceeds 5,800 full-length expression clones, covering more than 4,100 different human plasma membrane proteins, human tethered secreted proteins, and heterodimeric complexes, with many proteins represented by multiple variants.
Retrogenix is headquartered in Chinley in the High Peak, UK, and all project work is undertaken by highly skilled scientists in our specialist laboratory facilities on-site. The company also has a US office in Cambridge, MA. Retrogenix continues to build on its global reputation and the team is rapidly expanding to keep pace with the growing demand for its services.
"Successfully executed antibody specificity screen. Comprehensive data package and report."
Retrogenix has not received any endorsements.